Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2020-11, Vol.159 (5), p.1985-1987.e4
Hauptverfasser:	Noureddin, Mazen, Jones, Calum, Alkhouri, Naim, Gomez, Eduardo Vilar, Dieterich, Douglas T., Rinella, Mary E., Therapondos, George, Girgrah, Nigel, Mantry, Parvez S., Sussman, Norman L., Figueroa Diaz, Viviana, Fuchs, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Cirrhosis Cost-Benefit Analysis Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - economics Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - therapy Diagnostic Screening Programs - economics Fibrosis Health Care Costs Healthy Lifestyle High-risk population Humans Liver Cirrhosis - diagnosis Liver Cirrhosis - economics Liver Cirrhosis - epidemiology Markov Chains Models, Economic NASH Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - economics Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - therapy Predictive Value of Tests Quality of Life Quality-Adjusted Life Years Reproducibility of Results Risk Factors Risk Reduction Behavior Screening Treatment Outcome United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!